Patent application number | Description | Published |
20120032611 | LED EMITTING DEVICE AND DRIVING METHOD THEREOF - The present invention relates to an LED emitting device and a driving method thereof including at least two LED channels. | 02-09-2012 |
20120201019 | LED EMITTING DEVICE AND DRIVING METHOD THEREOF - The present invention relates to an LED light emitting device and a driving method thereof. The LED light emitting device supplies a power supply voltage to at least two LED channels. The LED light emitting device samples channel voltages of the at least two LED channels to detect a minimum voltage from among the sampled voltages, and amplifies a difference between the detected minimum voltage and a predetermined reference voltage to generate an error amplifying signal. The LED light emitting device generates an enable signal having a duty extended by a predetermined delay period from a duty of a dimming signal for controlling light emission periods of the at least two LED channels. In this instance, the error generator is operable by the enable signal. | 08-09-2012 |
20130293109 | LED DRIVER IC, DRIVING METHOD THEREOF, AND LED EMITTING DEVICE USING THE LED DRIVER IC AND THE DRIVING METHOD - The present invention relates to an LED driver IC, a driving method of the LED driver IC, and an LED light emission device using the LED driver IC. The LED light emission device includes an LED string, a power switch supplying power to the LED string, a dimming switch controlling light emission duty of the LED string, and an LED driver IC controlling switching operation of the power switch and the dimming switch. The LED driver IC senses a difference between a control electrode voltage of the dimming switch and a sense voltage generated according to a current flowing to the dimming switch, and triggers the OCP operation according to a result of comparison between the sensed voltage and a predetermined OCP reference voltage. | 11-07-2013 |
20140152266 | BATTERY MANAGEMENT SYSTEM AND MANAGING METHOD THEREOF - A battery management system and a driving method are provided. The battery management system performs a bleeding operation at a moment that a voltage of each cell becomes a reference voltage during an initial charging operation to smoothly change a slope of a charge voltage. Accordingly, the charging time of the cell initially charging at the low voltage is increased, thereby reducing the entire cell balancing period. | 06-05-2014 |
20140176080 | LOAD/CHARGER DETECTION CIRCUIT, BATTERY MANAGEMENT SYSTEM COMPRISING THE SAME AND DRIVING METHOD THEREOF - Disclosed are a load/charger detection circuit, a battery management system comprising the same and a driving method thereof. The load/charger detection circuit includes a current source; a current mirror connected to the current source to copy a current of the current mirror; at least two resistors connected between a first terminal providing a corresponding voltage to a charger or a load and a power supply; and a zener diode connected between the first terminal and the current mirror. | 06-26-2014 |
Patent application number | Description | Published |
20080207704 | HETEROARYL-IMIDAZOLE DERIVATIVES AS CANNABINOID CB1 RECEPTOR ANTAGONISTS - A heteroaryl-imidazole compound of formula (I) or a pharmaceutically acceptable salt thereof is effective as a cannabinoid CB | 08-28-2008 |
20080207705 | Heteroaryl-Imidazole Derivatives as Cannabinoid CB1 Receptor Antagonists - A novel heteroaryl-imidazole compound of formula (I) or a pharmaceutically acceptable salt thereof is effective as a cannabinoid CB | 08-28-2008 |
20080262066 | Azole Derivatives as Cannabinoid CB1 Receptor Antagonists - A novel azole compound of formula (I) or a pharmaceutically acceptable salt thereof is effective as a cannabinoid CB | 10-23-2008 |
20100113500 | ORALLY BIOAVAILABLE PRODUCTS OF (+)-3-HYDROXYMORPHINAN FOR PARKINSON'S DISEASE PREVENTION OR TREATMENT - The present invention is directed to a novel prodrug of (+)-3-hydroxymorphinan compound of formula (I) or a pharmaceutically acceptable salt thereof, a method for preparing the same, and its use for preventing or treating Parkinson's disease. | 05-06-2010 |
20110178091 | ARYLPIPERAZINE-CONTAINING PYRROLE 3-CARBOXAMIDE DERIVATIVES FOR TREATING DEPRESSIVE DISORDERS - The present invention relates to novel arylpiperazine-containing pyrrole 3-carboxamide derivatives of formula (I) or a pharmaceutically acceptable salt thereof which is useful for preventing or treating depressive disorders. The present invention also provides a method for preparing the arylpiperazine-containing pyrrole 3-carboxamide derivatives or the pharmaceutically acceptable salt thereof, a pharmaceutical composition containing same, and a method for preventing or treating depressive disorders. | 07-21-2011 |
20110178140 | SULFUR CONTAINING PYRAZOLE-HETEROCYCLE DERIVATIVES AS CANNABINOID CB1 RECEPTOR ANTAGONISTS - A novel sulfur containing heteroaryl-pyrazole compound of formula (I) or a pharmaceutically acceptable salt thereof is effective as a cannabinoid CB | 07-21-2011 |
20120101051 | NOVEL C-ARYL GLUCOSIDE SGLT2 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME - A novel C-aryl glucoside compound, or a pharmaceutically acceptable salt or a prodrug thereof having an inhibitory activity against sodium-dependent glucose cotransporter 2 (SGLT2) being present in the intestine and kidney; and a pharmaceutical composition comprising the same as an active ingredient, which is useful for preventing or treating metabolic disorders, particularly, diabetes, are provided. | 04-26-2012 |
20120115881 | NOVEL ARYLPIPERAZINE-CONTAINING IMIDAZOLE 4-CARBOXAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING SAME - A novel arylpiperazine-containing imidazole 4-carboxamide derivative or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same as an active ingredient for preventing or treating a depressive disorder are provided. | 05-10-2012 |
20120122848 | (+)-3-HYDROXYMORPHINAN DERIVATIVES AS NEUROPROTECTANTS - A novel (+)-3-hydroxymorphinan derivatives and a pharmaceutical composition comprising the same as an active ingredient, which are useful for preventing or treating a neurodegenerative disease, are provided. | 05-17-2012 |
20120136149 | METHOD FOR PREPARING 5-CHLORO-N-(METHYL)THIOPHEN-2-CARBOXAMIDE DERIVATIVE AND INTERMEDIATE USED THEREIN - Disclosed are: a method for preparing a 5-chloro-N-({(5S)-2-oxo-3-[4-(5,6-dihydro-4H-[1,2,4]triazin- | 05-31-2012 |
20120232090 | ARYLPIPERAZINE-CONTAINING PURINE DERIVATIVES AND USES THEREOF - A novel arylpiperazine-containing purine derivatives and a pharmaceutical composition comprising the same as an active ingredient, which are useful for preventing or treating depressive disorders, are provided. | 09-13-2012 |
20130090298 | Thiazole Derivatives as SGLT2 Inhibitors and Pharmaceutical Composition Comprising Same - The present invention relates to a novel compound with thiazole ring having an inhibitory activity against sodium-dependent glucose cotransporter 2 (SGLT2) being present in the intestine and kidney, and a pharmaceutical composition comprising the same as an active ingredient, which is useful for preventing or treating metabolic disorders, particularly diabetes. | 04-11-2013 |
20130172278 | NOVEL THIOPHENE DERIVATIVE AS SGLT2 INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME - The present invention relates to a novel compound with thiophene ring having an inhibitory activity against sodium-dependent glucose cotransporter 2 (SGLT2) being present in the intestine and kidney, and a pharmaceutical composition comprising the same as an active ingredient, which is useful for preventing or treating metabolic disorders, particularly diabetes. The prevention also provides a method for preparing same, a pharmaceutical composition containing same, and a method for preventing or treating metabolic disorders, particularly diabetes. | 07-04-2013 |
20130217672 | (+)-3-HYDROXYMORPHINAN-BASED POLYCYCLE DERIVATIVES - A (+)-3-hydroxymorphinan-based polycycle derivative of formula (I) is effective as a neuroprotective agent for neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and ischemic stroke. | 08-22-2013 |